Current Investment Portfolio

Historic Investment Portfolio

Exits via M&A

M&A

• Afferent (acquired by Merck)
• Alios (acquired by Johnson+Johnson)
• Ambit (acquired by Daiichi Sankyo)
• Ambrx (acquired by Wuxi)
• Artus (acquired by Qiagen)
• Avexis (acquired by Novartis)
• BioFire (acquired by bioMérieux)
• BioXell (acquired by Cosmo)
• CGI (acquired by Gilead)
• DVS (acquired by Fluidigm)
• Envoy (acquired by Takeda)
• Flatiron (acquired by Roche)
• Foundation Medicine (acquired by Roche)
• HistoRx (acquired by Genoptix)
• Leukosite (acquired by Millennium)
• Memory (acquired by Roche)
• Miikana (acquired by EntreMed)
• MySugr (acquired by Roche)
• Sequana (acquired by Celera)
• Stratos Genomics (acquired by Roche)
• Syrrx (acquired by Takeda)
• Tripath (acquired by Becton Dickinson)
• Viewics (acquired by Roche)

Historic Investment Portfolio

Exits via IPO

IPOs

• Addex
• Anadys
• Caliper
• Complete Genomics
• Conatus
• CV Therapeutics
• CytomX
• deCode
• Fibrogen, Inc
• Halozyme Therapeutics
• Horizon Discovery
• Pharmasset
• Protein Design Labs, Inc
• Sutrovax
• Taimed
• TiGenix
• Xenon